Sybrava 284mg Injection

About

Sybrava 284 mg Injection contains Inclisiran as its active ingredient, a medication classified under proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. It is the first and only small interfering RNA (siRNA) therapy developed to reduce low-density lipoprotein (LDL) cholesterol levels. Sybrava is prescribed as an add-on to statin therapy and dietary modifications for patients with primary hypercholesterolemia (high cholesterol).

This medication should not be used if you are allergic to Inclisiran or any of its components. It is not recommended during pregnancy or breastfeeding—consult your doctor for further guidance. Sybrava is also not approved for use in children and adolescents under 18 years of age.

Before starting Sybrava 284 mg, you should already be on a cholesterol-lowering diet and taking a statin. Continue both the diet and statin therapy for the entire duration of treatment with Sybrava unless advised otherwise by your doctor. Do not stop this medication without medical consultation.

Inform your doctor if you have any kidney or liver disorders, respiratory issues, heart conditions, or sugar intolerance. Also, let your physician or pharmacist know about any other medicines you are currently taking, have recently taken, or plan to take—including over-the-counter drugs and herbal supplements.

• Combination to other statin therapy and diet for treating primary hyperlipidemia [heterozygous familial hypercholesterolemia]

Directions for use

This medicine will be administered by your doctor or nurse. Please do not attempt to self-administer it.

Common:

• Injection site reactions like redness, rash and pain
• Arthralgia
• Bronchitis
• Fever
• Chills
• Headache

Safety Measures

Alcohol - The safety of consuming alcohol while receiving Sybrava 284 mg Injection is not known. It is advisable to consult your physician before consuming alcoholic beverages during treatment.
Pregnancy - Sybrava 284 mg Injection is not recommended during pregnancy, as it may cause harm to the unborn baby. Inform your doctor if you are pregnant, think you might be pregnant, or are planning to conceive before starting the treatment.
Breastfeeding - It is not known whether Sybrava 284 mg Injection passes into breast milk. Consult your doctor before using this medication while breastfeeding. Your doctor will weigh the potential benefits against the possible risks before prescribing it.
Liver - Sybrava 284 mg Injection is mainly metabolized in the liver. Inform your healthcare provider if you have any liver conditions or a history of liver disease before starting the treatment.
Lungs - The safety of Sybrava 284 mg Injection in patients with lung conditions is not established. Consult your doctor if you have any lung disease before beginning treatment.

Disclaimer

Med E Hub is committed to delivering reliable, expert-reviewed information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.